Hot super-Earths stripped by their host stars.

Simulations predict that hot super-Earth sized exoplanets can have their envelopes stripped by photoevaporation, which would present itself as a lack of these exoplanets. However, this absence in the exoplanet population has escaped a firm detection. Here we demonstrate, using asteroseismology on a sample of exoplanets and exoplanet candidates observed during the Kepler mission that, while there is an abundance of super-Earth sized exoplanets with low incident fluxes, none are found with high incident fluxes. We do not find any exoplanets with radii between 2.2 and 3.8 Earth radii with incident flux above 650 times the incident flux on Earth. This gap in the population of exoplanets is explained by evaporation of volatile elements and thus supports the predictions. The confirmation of a hot-super-Earth desert caused by evaporation will add an important constraint on simulations of planetary systems, since they must be able to reproduce the dearth of close-in super-Earths.

A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.

Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine treatment. CGRP is a potent vasodilator that is elevated after myocardial infarction, and it delays ischemia during treadmill exercise. We tested the hypothesis that CGRP receptor antagonism does not reduce treadmill exercise time (TET). The effects of supratherapeutic doses of telcagepant on TET were assessed in a double-blind, randomized, placebo-controlled, two-period, crossover study in patients with stable angina and reproducible exercise-induced angina. Patients received telcagepant (600 mg, n = 46; and 900 mg, n = 14) or placebo and performed treadmill exercise at T(max) (2.5 h after the dose). The hypothesis that telcagepant does not reduce TET was supported if the lower bound of the two-sided 90% confidence interval (CI) for the mean treatment difference (telcagepant-placebo) in TET was more than -60 s. There were no significant between-treatment differences in TET (mean treatment difference: -6.90 (90% CI: -17.66, 3.86) seconds), maximum exercise heart rate, or time to 1-mm ST-segment depression using pooled data or with stratification for dose.

In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

Two different cellular assay models were assessed as in vitro systems for P-glycoprotein (P-gp) substrate identification: cellular accumulation studies with KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line; and transcellular transport studies with L-MDR1 (or L-mdr1a), a human MDR1 (or mouse mdr1a)-transfected porcine renal epithelial cell line. The in vitro-in vivo correlation for P-gp-mediated transport activity was also examined by comparing in vitro data obtained from L-mdr1a cell studies and in vivo data from mdr1a (-/-)/(+/+) CF-1 mice studies for several compounds. The results are summarized as follows: 1) two in vitro assay systems routinely identified the substrate for human MDR1 P-gp-mediated transport with similar quantitative results; 2) in vitro studies with L-MDR1 and L-mdr1a cells demonstrated that the P-gp substrate susceptibility is different between human and mouse for certain compounds (species difference); and 3) in vivo brain concentration ratios of mdr1a (-/-) to (+/+) CF-1 mice, either at a certain time point or up to 60 min, correlated well with the in vitro transcellular transport ratios from L-mdr1a cells (r(2) = 0.968 and 0.926, respectively). This indicates that, at least in mice, the in vitro data are valid predictors of the in vivo contribution of P-gp: the contribution of P-gp to the distribution of the compound to the brain up to 60 min post i.v. administration. These results provide a rationale for predicting in vivo relevance of P-gp in human from in vitro data using human P-gp-expressing cells.

Cholesterol esterification by mammary gland microsomes from the lactating rat.

Cholesterol esterification by fatty acyl-CoA:cholesterol acyltransferase (ACAT, EC 2.3.1.26) has been demonstrated in microsomes prepared from breast tissue of the lactating rat, employing the incorporation of [1-14C]oleoyl coenzyme-A into cholesteryl[14C]oleate. The regulation of this activity in vitro was studied by supplementing microsomes with unesterified cholesterol supplied either as a dispersion in acetone or by incubating microsomes with cholesterol-enriched serum lipoproteins prior to enzyme assay. ACAT activity was increased by more than 80% when the ratio of unesterified cholesterol to microsomal protein was increased from 29 to 48 micrograms/mg protein, indicating that the normal cholesterol content of mammary gland microsomes does not saturate this enzyme. Cholesterol esterification could be inhibited nearly completely in vitro by addition of the polar steroid progesterone (93% decrease in ACAT activity with 75 microM progesterone) and, to lesser extents, by estradiol and retinol. Enzyme assays were also performed after incubating microsomes with N-acylamides that inhibit cholesteryl ester synthesis in other systems. Under conditions where the mammary gland ACAT reaction was inhibited by more than 82%, the esterification of retinol was reduced by less than 30% and incorporation of [14C]oleoyl-CoA into triglycerides was not inhibited at all. These studies indicate that the lactating mammary gland contains ACAT activity having properties similar to ACAT in other organs. The presence of ACAT activity in the lactating mammary gland provides a possible mechanism for the synthesis of cholesteryl esters found in milk. It can also be inferred that ACAT in mammary gland microsomes is likely to be distinct from the microsomal acyltransferases that catalyze the esterification of retinol and glycerides.